New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

11

Moderna starts trial for Omicron-specific booster shot

Moderna Inc. started a mid-stage study, testing a booster dose of the company’s COVID-19 vaccine specifically designed to target the Omicron coronavirus variant, a day after rival Pfizer Inc. launched a similar trial.

12

Pfizer, Moderna shots safe during in vitro fertilization; healthy gut bacteria may help prevent long COVID

COVID-19 vaccines using mRNA technology do not affect fertility outcomes during in-vitro fertilization (IVF), researchers found. Other new findings suggest the bacteria living in the small intestine may contribute to the risk for long COVID after infection with SARS-CoV-2.

13

Galvani Bioelectronics Announces World’s First Investigational Treatment of Rheumatoid Arthritis Using Splenic Nerve Stimulation

Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.

14

Abbott profit, sales beat estimates on vigorous COVID test demand

Abbott Laboratories beat fourth-quarter 2021 profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for the company’s diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.

15

BlueWillow’s Non-Viral Intranasal Vaccine Enhances Immunity and Broadens Options

BlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.

18

Money on the Move: January 19 – 25

Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

19

Cortexyme Crashes as Key Alzheimer’s Asset Hit with Clinical Hold

South San Francisco-based Cortexyme Inc. received a letter from the U.S. Food and Drug Administration on January 25 placing a full clinical hold on the Investigational New Drug application for the company’s lead clinical asset atuzaginstat, which is in development for the treatment of Alzheimer’s disease.

20

COVID-19 cases at highest ever in Americas – regional health agency

New cases of COVID-19 in the Americas in the past week were the highest since the pandemic began and the very contagious Omicron variant has clearly become the predominant strain, the Pan American Health Organization said on January 26.